Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

After ten years of research, scientists have made a major step toward solving one of the biggest challenges in kidney transplants finding a perfect match between donor and recipient blood types.A team ...

After a decade of work, researchers are closer than ever to a key breakthrough in kidney organ transplants: being able to ...

As concerns over contaminated cough syrups resurface, experts warn that certain formulations can be toxic for children, ...